Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2014 · 10-Q
Revenue$1.82M$1.82M+48.5% vs Q3 2013 Net Income-$294.54K-$294.54KN/M vs Q3 2013 EPS Diluted-$0.02-$0.02— vs Q3 2013 Gross Profit$861,087+2.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived-$179,377N/M Free Cash Flowderived-$180,479N/M Margins · derivedGross margin47.3%−21.6 pt vs Q3 2013
Operating margin-16.2%−4.6 pt vs Q3 2013
Net margin-16.2%+17.4 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 13, 2014 · 44 d after period end